222 related articles for article (PubMed ID: 30877232)
1. Dependence on Myb expression is attenuated in myeloid leukaemia with N-terminal CEBPA mutations.
Volpe G; Cauchy P; Walton DS; Ward C; Blakemore D; Bayley R; Clarke ML; Schmidt L; Nerlov C; Garcia P; Dumon S; Grebien F; Frampton J
Life Sci Alliance; 2019 Apr; 2(2):. PubMed ID: 30877232
[TBL] [Abstract][Full Text] [Related]
2. Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML.
Heyes E; Schmidt L; Manhart G; Eder T; Proietti L; Grebien F
Leukemia; 2021 Sep; 35(9):2526-2538. PubMed ID: 33623142
[TBL] [Abstract][Full Text] [Related]
3. C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription.
Du M; Wang M; Liu M; Fu S; Lin Y; Huo Y; Yu J; Yu X; Wang C; Xiao H; Wang L
J Exp Clin Cancer Res; 2024 Mar; 43(1):79. PubMed ID: 38475919
[TBL] [Abstract][Full Text] [Related]
4. The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression.
Kuo YY; Hou HA; Chen YK; Li LY; Chen PH; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Chou WC; Liu CY; Tang JL; Yao M; Tien HF
Haematologica; 2014 Dec; 99(12):1799-807. PubMed ID: 25193961
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
Hickey CJ; Schwind S; Radomska HS; Dorrance AM; Santhanam R; Mishra A; Wu YZ; Alachkar H; Maharry K; Nicolet D; Mrózek K; Walker A; Eiring AM; Whitman SP; Becker H; Perrotti D; Wu LC; Zhao X; Fehniger TA; Vij R; Byrd JC; Blum W; Lee LJ; Caligiuri MA; Bloomfield CD; Garzon R; Marcucci G
Blood; 2013 Jan; 121(1):159-69. PubMed ID: 23100311
[TBL] [Abstract][Full Text] [Related]
6. C/EBPα and MYB regulate FLT3 expression in AML.
Volpe G; Walton DS; Del Pozzo W; Garcia P; Dassé E; O'Neill LP; Griffiths M; Frampton J; Dumon S
Leukemia; 2013 Jul; 27(7):1487-96. PubMed ID: 23340802
[TBL] [Abstract][Full Text] [Related]
7. The +37 kb Cebpa Enhancer Is Critical for Cebpa Myeloid Gene Expression and Contains Functional Sites that Bind SCL, GATA2, C/EBPα, PU.1, and Additional Ets Factors.
Cooper S; Guo H; Friedman AD
PLoS One; 2015; 10(5):e0126385. PubMed ID: 25938608
[TBL] [Abstract][Full Text] [Related]
8.
Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
[TBL] [Abstract][Full Text] [Related]
9. C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.
Pulikkan JA; Peramangalam PS; Dengler V; Ho PA; Preudhomme C; Meshinchi S; Christopeit M; Nibourel O; Müller-Tidow C; Bohlander SK; Tenen DG; Behre G
Blood; 2010 Dec; 116(25):5638-49. PubMed ID: 20889924
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.
Grebien F; Vedadi M; Getlik M; Giambruno R; Grover A; Avellino R; Skucha A; Vittori S; Kuznetsova E; Smil D; Barsyte-Lovejoy D; Li F; Poda G; Schapira M; Wu H; Dong A; Senisterra G; Stukalov A; Huber KVM; Schönegger A; Marcellus R; Bilban M; Bock C; Brown PJ; Zuber J; Bennett KL; Al-Awar R; Delwel R; Nerlov C; Arrowsmith CH; Superti-Furga G
Nat Chem Biol; 2015 Aug; 11(8):571-578. PubMed ID: 26167872
[TBL] [Abstract][Full Text] [Related]
11. CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.
Schmidt L; Heyes E; Scheiblecker L; Eder T; Volpe G; Frampton J; Nerlov C; Valent P; Grembecka J; Grebien F
Leukemia; 2019 Jul; 33(7):1608-1619. PubMed ID: 30679799
[TBL] [Abstract][Full Text] [Related]
12. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
Pabst T; Mueller BU; Zhang P; Radomska HS; Narravula S; Schnittger S; Behre G; Hiddemann W; Tenen DG
Nat Genet; 2001 Mar; 27(3):263-70. PubMed ID: 11242107
[TBL] [Abstract][Full Text] [Related]
13. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
[TBL] [Abstract][Full Text] [Related]
14. [Roles of CEBPA mutation and expression abnormality in acute myeloid leukemia - review].
Wang LM; Xiao HW; Huang H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1256-60. PubMed ID: 23114160
[TBL] [Abstract][Full Text] [Related]
15. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
[TBL] [Abstract][Full Text] [Related]
16. Transcription factor C/EBPα-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia.
Katzerke C; Madan V; Gerloff D; Bräuer-Hartmann D; Hartmann JU; Wurm AA; Müller-Tidow C; Schnittger S; Tenen DG; Niederwieser D; Behre G
Blood; 2013 Oct; 122(14):2433-42. PubMed ID: 23974200
[TBL] [Abstract][Full Text] [Related]
17. Gain-of-Function Effects of N-Terminal CEBPA Mutations in Acute Myeloid Leukemia.
Schmidt L; Heyes E; Grebien F
Bioessays; 2020 Feb; 42(2):e1900178. PubMed ID: 31867767
[TBL] [Abstract][Full Text] [Related]
18. C/EBPα-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia.
Hughes JM; Legnini I; Salvatori B; Masciarelli S; Marchioni M; Fazi F; Morlando M; Bozzoni I; Fatica A
Oncotarget; 2015 Jul; 6(21):18534-44. PubMed ID: 26053097
[TBL] [Abstract][Full Text] [Related]
19. HoxA9 binds and represses the Cebpa +8 kb enhancer.
Peng L; Guo H; Ma P; Sun Y; Dennison L; Aplan PD; Hess JL; Friedman AD
PLoS One; 2019; 14(5):e0217604. PubMed ID: 31120998
[TBL] [Abstract][Full Text] [Related]
20. CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance.
Wilhelmson AS; Porse BT
Br J Haematol; 2020 Aug; 190(4):495-507. PubMed ID: 32086816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
